InSightec announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE Mark for the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease, and neuropathic pain.
InSightec recently received its second ExAblate U.S. Food and Drug Administration (FDA) approval for the treatment of bone metastases in patients who are unable or unwilling to undergo radiation. In 2004, the device received approval from the FDA for use with uterine fibroids, the company said.
